Teleflex Incorporated (TFX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Teleflex Incorporated (TFX) Healthcare & Pipeline Overview

Teleflex Incorporated is a global provider of single-use medical devices for critical care and surgical applications. With a focus on vascular access, interventional, anesthesia, and urology products, Teleflex serves hospitals, healthcare providers, and medical device manufacturers, maintaining a competitive edge through its established brands and innovative technologies.

What Is the Investment Thesis for TFX?

Teleflex Incorporated presents a mixed investment thesis. The company's established position in the medical device market, particularly with its Arrow and UroLift brands, provides a stable revenue base. The dividend yield of 1.10% offers a modest return to investors. However, the negative profit margin of -30.6% raises concerns about profitability. Growth catalysts include expanding the UroLift System's market penetration and introducing innovative vascular access products. Potential risks include increased competition in the medical device industry and regulatory hurdles for new product approvals. Investors should carefully weigh the growth opportunities against the profitability challenges and competitive pressures.

Based on FMP financials and quantitative analysis

TFX Key Highlights

Market capitalization of $5.84B reflects Teleflex's significant presence in the medical device market.

• Gross margin of 53.3% indicates strong pricing power and efficient manufacturing processes.
• Dividend yield of 1.10% provides a steady income stream for investors.
• Beta of 0.83 suggests lower volatility compared to the overall market.
• Negative profit margin of -30.6% signals potential challenges in achieving profitability.

Who Are TFX's Competitors?

TFX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TFX's Key Strengths?

Strong brand recognition with established brands like Arrow and UroLift.

• Diverse product portfolio across multiple therapeutic areas.
• Global presence with sales in various countries.
• Focus on single-use devices provides recurring revenue.

What Are TFX's Weaknesses?

Negative profit margin indicates potential profitability issues.

• Reliance on single-use devices may be affected by environmental concerns.
• Exposure to regulatory risks and compliance costs.
• Dependence on third-party distributors in some markets.

What Could Drive TFX Stock Higher?

New product launches in vascular access and interventional cardiology.

• Expansion of the UroLift System into international markets.
• Strategic acquisitions of companies with complementary technologies.
• Increased adoption of minimally invasive procedures in healthcare.

What Are the Key Risks for TFX?

Negative return on equity (-31.8%) — the business is not currently generating profit on shareholder capital.

• Increased competition from established and emerging medical device companies.
• Regulatory hurdles and delays in product approvals.
• Product liability claims and recalls.
• Pricing pressures from healthcare providers and payers.
• Fluctuations in foreign exchange rates.

What Are the Growth Opportunities for TFX?

• Expansion of the UroLift System: The UroLift System, a minimally invasive technology for treating benign prostatic hyperplasia, presents a significant growth opportunity. The global market for BPH treatment is substantial, and UroLift's efficacy and safety profile positions it well for increased adoption. Teleflex can drive growth by expanding its salesforce, increasing physician awareness, and securing favorable reimbursement policies. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Innovation in Vascular Access Products: Teleflex's Arrow brand is a leader in vascular access products. Continued innovation in this area, such as developing new catheter designs, navigation systems, and antimicrobial technologies, can drive growth. The market for vascular access devices is expanding due to the increasing use of intravenous therapies and diagnostic procedures. Teleflex can maintain its competitive edge by investing in R&D and launching innovative products that address unmet clinical needs. Expect new product launches within the next 2 years.
• Strategic Acquisitions: Teleflex has a history of strategic acquisitions to expand its product portfolio and geographic reach. Pursuing additional acquisitions of companies with complementary technologies or market access can accelerate growth. Potential acquisition targets include companies specializing in minimally invasive surgical devices, advanced wound care products, or remote patient monitoring solutions. Acquisitions can provide access to new markets and technologies, driving long-term growth.
• Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, offer significant growth opportunities for Teleflex. These markets have a large and growing population, increasing healthcare spending, and unmet medical needs. Teleflex can expand its presence in these markets by establishing local sales and distribution networks, adapting its products to local needs, and partnering with local healthcare providers. Expect increased focus on these markets over the next 5 years.
• Development of Respiratory Products: Teleflex's respiratory product line, including oxygen and aerosol therapies, spirometry, and ventilation management products, presents another growth avenue. The global market for respiratory devices is expanding due to the increasing prevalence of respiratory diseases, such as asthma and COPD. Teleflex can drive growth by developing innovative respiratory products that improve patient outcomes and reduce healthcare costs. This includes focusing on home healthcare solutions and remote monitoring technologies.

What Are TFX's Competitive Advantages?

• Established brands (e.g., Arrow, UroLift) provide brand recognition and customer loyalty.
• Proprietary technologies and patents protect its products from competition.
• Extensive distribution network ensures broad market access.
• Strong relationships with healthcare providers facilitate product adoption.
• Regulatory expertise and compliance capabilities create barriers to entry.

What Does TFX Do?

Teleflex Incorporated, founded in 1943 and headquartered in Wayne, Pennsylvania, is a global company focused on designing, developing, manufacturing, and supplying single-use medical devices. The company's products are utilized in a wide range of diagnostic and therapeutic procedures, primarily in critical care and surgical settings. Teleflex offers a diverse portfolio, including vascular access products under the Arrow brand, which encompass catheters, navigation systems, and intraosseous access systems. These products facilitate intravenous therapies, blood pressure measurement, and blood sampling. The company's interventional products include coronary catheters, structural heart therapies, and peripheral intervention devices. Teleflex also provides anesthesia products, such as airway and pain management solutions, and surgical products, including ligation clips and fascial closure systems. A key product is the UroLift System, used for treating lower urinary tract symptoms related to benign prostatic hyperplasia. Teleflex serves hospitals, healthcare providers, medical device manufacturers, and home care markets worldwide. Through strategic acquisitions and organic growth, Teleflex has expanded its product offerings and geographic reach, solidifying its position as a leading player in the medical device industry.

What Products and Services Does TFX Offer?

• Designs and manufactures single-use medical devices.
• Provides vascular access products, including catheters and navigation systems.
• Offers interventional products for cardiology and radiology.
• Supplies anesthesia products for airway and pain management.
• Develops surgical products, including ligation clips and closure systems.
• Provides interventional urology products, such as the UroLift System.
• Offers respiratory products for oxygen and ventilation management.
• Provides urology products, including catheters and accessories.

How Does TFX Make Money?

• Develops and manufactures medical devices.
• Sells products to hospitals, healthcare providers, and medical device manufacturers.
• Generates revenue through direct sales and distribution networks.
• Focuses on single-use devices to ensure recurring revenue.
• Invests in research and development to innovate and expand product offerings.

What Industry Does TFX Operate In?

Teleflex Incorporated operates in the medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and intense competition. The global medical device market is projected to grow, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Teleflex competes with other medical device manufacturers, including ARWR: Arrowhead Pharmaceuticals, Inc., PCVX: Vaxcyte, Inc., KRYS: Krystal Biotech, Inc., ALKS: Alkermes plc, and PTCT: PTC Therapeutics, Inc. Teleflex's focus on single-use devices and specialized products positions it to capitalize on the growing demand for minimally invasive procedures and advanced medical technologies.

Who Are TFX's Key Customers?

• Healthcare providers
• Medical device manufacturers
• Home care markets
• Emergency medicine channels

Company Profile

Teleflex Incorporated operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Wayne, US. The company is led by CEO Jason Weidman. TFX has traded publicly since 1980.

Return on equity for Teleflex Incorporated stands at -31.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.8%, the inverse of the P/E and a quick read on earnings relative to price.

TFX Valuation & Market Position

With a $5.84B market cap, Teleflex Incorporated sits in the mid-cap segment of the market. Analyst price targets span from $140.00 to $170.00, with a consensus of $155.25. At the current price of $132.00, that implies approximately 18% upside potential. Relative to its peer group, TFX's quantitative score of 55/100 is roughly in line with the peer average of 60/100.

Quarterly Financial Performance: Teleflex Incorporated

Revenue for Teleflex Incorporated came in at $570.3M during Q2 FY2026, a 4.0% improvement versus the preceding quarter. The company recorded net income of $102.0M, with diluted EPS of $2.34. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, TFX averaged $-5.81 in diluted EPS.

Teleflex Incorporated's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.01 places it in the grey zone, a middle ground that warrants monitoring.

Teleflex Incorporated has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.6% above estimates on average.

Over the past six months, Teleflex Incorporated insiders filed 21 SEC Form 4 transactions — 2 sales and 19 purchases. On net that is roughly 112K shares acquired (about $5.9M) — insiders putting money in tends to read as conviction.

TFX Financials

TFX Latest News

TFX Analyst Consensus

TFX MoonshotScore

Latest Teleflex Incorporated Analysis

TFX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources